Male Vitality Supplement Guide

Walk the male vitality section of any supplement retailer and the same eight or nine botanical names recur across dozens of products. Maca, tribulus, horny goat weed, ashwagandha, L-arginine, muira puama, catuaba, ginseng, green tea. The formulas differ in packaging far more than in composition.

That is not a conspiracy. It is what happens when a category has a small number of ingredients with any published human record at all, and every manufacturer reads the same reviews. An analysis of the products actually on sale found exactly that pattern: a narrow ingredient pool, heavily repeated, at amounts that rarely match the trials.

What differs between two jars on that shelf is therefore not usually which plants are in them. It is three other things: how much of each, whether you are told how much, and what the seller is willing to claim.

Those three are what this guide is about. It does not walk the ingredients one at a time, because that list is available anywhere. It covers how to judge a claim about any of them.

Almost every claim in this category rests on one of three kinds of study, and they are not interchangeable. Knowing which tier a claim comes from settles most arguments before they start.

Every tier produces real findings. The error is attaching a tier-three result to a tier-one sentence.

The move to watch for is a sales page that describes a laboratory result in the language of a clinical one. The icariin enzyme study is a genuine piece of chemistry: icariin inhibits human PDE5 at an IC50 of 5.9 micromolar in a test tube, and the compounds that come close to a prescription drug's potency are synthetic derivatives chemists built.

The follow-up work used 10 mg per kilogram in rats. Neither is a human outcome, and a sentence that puts either beside a prescription tablet has crossed two tiers in one breath.

The same test applies in the other direction. The one relaxation study everyone cites for catuaba tested Catuama, a four-herb Brazilian preparation, on strips of rabbit tissue at 1 to 10 mg. Tissue in a bath is not a man and four herbs are not one herb.

Most people read a dose as a dial: more does more, less does less, and half a dose does half as much. In this category that intuition is wrong more often than it is right, because several of the best-studied ingredients behave as thresholds instead.

L-arginine is the clean worked example. The trial that produced a result used 5,000 mg a day for six weeks. A crossover at 1,500 mg a day performed no better than placebo. The pooled meta-analysis spans that whole range, and the blood-pressure dose-response work needed 4,000 mg a day and upwards before pressure moved at all.

So 1,500 mg is not three tenths of an effect. On the published evidence it is no effect. That is what a threshold means, and it is why a product carrying a tenth of the lower figure cannot be described as carrying a tenth of the benefit.

Maca shows the same shape from a different direction. The dose-finding study compared 3.0 g a day against 1.5 g a day and found the higher dose moved its outcome while the lower one did not. Same plant, same trial, same measurement, twofold difference in dose, and one arm worked.

Once you have seen that twice, the arithmetic on a label stops being pedantry. A figure below a published threshold is not a smaller version of the trial; it is outside what the trial tested.

Read across this category with a calculator and one pattern dominates everything else. The trials that worked are measured in grams. The labels are measured in milligrams, and often in tens of milligrams.

Doses as the abstracts state them. The ashwagandha rows differ because the two trials measured different things in different units.

Set a typical multi-ingredient blend beside that table and the mismatch is usually an order of magnitude or two, not a near miss. A blend total in the tens of milligrams shared across eight or nine names cannot reach a gram-level figure for any of them, and no amount of extract-ratio footnoting changes the arithmetic.

The ashwagandha rows are the exception worth understanding, because they show the one honest route to a small number. The vitality crossover used an extract standardised to deliver 21 mg a day of withanolide glycosides. A small figure of a standardised active fraction is a real dose. A small figure of unstandardised whole-herb extract is not the same thing, and a label that prints no standardisation is not claiming it.

A large part of this shelf is sold on an implied hormonal mechanism. Three separate results, from three different ingredients, point the other way, and they are worth knowing because they are measurements rather than opinions.

• Tribulus. The androgen study in young men gave 10 to 20 mg per kilogram of body weight a day and measured no change in testosterone, androstenedione or luteinising hormone. An 800 mg a day trial and a 450 mg a day trial were both negative on their primary outcomes.
• Maca. The hormone arm of the maca work gave 1,500 or 3,000 mg a day and found no reproductive hormone changed. The desire result in the 2002 trial happened anyway, explicitly without a hormonal explanation.
• Ashwagandha. The 2026 hormone meta-analysis pooled the randomised evidence and found no change in TSH or T3.

The maca result is the interesting one, because it is positive and it is not hormonal. Self-rated desire rose from week eight while measured hormones did not move, which is a real finding and a reminder that a mechanism nobody can name is not the same as an effect nobody measured.

The practical upshot is narrow and useful. A product claiming to raise testosterone is claiming something these three measurements did not find, and a product claiming to support desire has at least one trial behind the idea at a gram-level dose.

A 2022 scoping review of botanicals and the testis reaches the same place from a wider angle: a large literature, a small number of controlled human outcomes, and a persistent gap between what is sold and what has been measured.

A proprietary blend is a labelling format written into United States regulation rather than a way of hiding something. Its members are listed in descending order of predominance by weight, and the blend carries a single total.

Descending order of predominance is the rule. Read with it, a blend line carries more information than most readers expect and less than a full panel.

There is one trick worth knowing, and it is free. If a blend breaks out a single ingredient with a printed figure, every name listed after it weighs no more than that figure. One printed number fixes a ceiling for the whole tail of the list.

That is often the single most informative thing on a blend label, and almost nobody uses it.

What the format cannot do is let anybody compare a product against a published protocol. A trial used a stated amount of one thing, and a blend states a total for several. The two are not commensurable, and a page that implies otherwise is borrowing a trial's credibility for a number it never tested.

Not, mostly, with the botanicals at the amounts typically sold. Two specific literatures are worth reading and both concern concentrated extracts at hundreds of milligrams a day.

The honest summary is that this category's safety profile is dominated by dose and by what else somebody is taking, rather than by the plants themselves. A blend carrying tens of milligrams shared across nine names sits far below every amount in either liver literature.

Which is not the same as saying a small dose is automatically safe for everybody. Anyone who has had a supplement-related liver problem before has the best available predictor of the next one.

Supports circulation. Supports libido. Supports stamina. Supports male vitality. The phrasing recurs because a dietary supplement in the United States may make structure-function claims and may not make disease claims, and those four are the category's version of the permitted form.

A structure-function claim says a product supports the normal function of a part of the body. A disease claim says it treats, prevents or cures a condition. The first is allowed with a disclaimer; the second turns the product into an unapproved drug.

That is why the whole shelf reads the same. It is not marketers running out of ideas, it is a ceiling everybody is writing up to.

• Supports is the word doing the legal work in all four phrases.
• The disclaimer is required alongside them: these statements have not been evaluated by the Food and Drug Administration, and the product is not intended to diagnose, treat, cure or prevent any disease.
• No supplement in this category is FDA-approved, because supplements are not approved before sale. A facility registration is a filing.
• A page that names a condition has stepped over the line, whatever the small print underneath says.

Reading the four words as the ceiling rather than as the pitch is the single most useful adjustment a buyer can make in this aisle. They describe what a seller is permitted to say, not what the product has been shown to do.

Applied to the jar this website sells: VigorHorse prints a complete panel, which a good part of this shelf does not, and it prints one amount, 82 mg, for 9 actives with caffeine broken out at 5 mg. The rank order is therefore readable and the per-name amounts are not, and every active except caffeine sits far below the gram-level doses above.

The full arithmetic is on the ingredients page, where it belongs. This guide exists so that page can be read critically rather than taken on trust.